Option delistings effective August 19th include Assembly Biosciences (ASMB), Bio-Path Holdings (BPTH), Cyclacel Pharmaceuticals (CYCC), MSP Recovery Inc (LIFW), Northern Star Investment Corp II (NSTB), Natura &co Holding S.a. (NTCOY), Nuvve Holding Corp (NVVE), TNF PHARMACEUTICALS, INC (TNFA), Tusimple Holdings Inc (TSPH), Titan Pharmaceuticals (TTNP), and Uxin Ltd (UXIN).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences reports Q2 EPS ($1.98) , one estimate ($2.23)
- Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
- ASMB Earnings this Week: How Will it Perform?
- Assembly Biosciences presents preclinical data of investigational HSV portfoli
- Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop